Vertex Pharmaceuticals (VRTX) Outperforms Broader Market: What You Need to Know

Company Performance - Vertex Pharmaceuticals (VRTX) closed at $509.47, with a daily increase of +1.19%, outperforming the S&P 500 which gained 0.15% [1] - Over the past month, VRTX shares increased by 3.87%, while the Medical sector declined by 4.39% and the S&P 500 fell by 0.21% [1] Upcoming Earnings - The earnings report for Vertex Pharmaceuticals is expected on May 5, 2025, with an anticipated EPS of $4.22, reflecting an 11.34% decrease compared to the same quarter last year [2] - Revenue is projected to be $2.82 billion, indicating a 4.76% increase year-over-year [2] Annual Forecast - Zacks Consensus Estimates predict earnings of $17.69 per share and revenue of $11.86 billion for the year, representing increases of +4111.9% and +7.63% respectively compared to the previous year [3] Analyst Estimates - Recent changes to analyst estimates for Vertex Pharmaceuticals are important as they reflect the evolving business landscape [4] - Positive estimate revisions are viewed as a sign of optimism regarding the company's outlook [4] Zacks Rank - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently ranks Vertex Pharmaceuticals at 3 (Hold) [6] - Over the past month, the Zacks Consensus EPS estimate has decreased by 0.61% [6] Valuation Metrics - Vertex Pharmaceuticals has a Forward P/E ratio of 28.47, which is higher than the industry average of 17.05 [7] - The company has a PEG ratio of 0.89, compared to the industry average PEG ratio of 1.33 [8] Industry Context - The Medical - Biomedical and Genetics industry, which includes Vertex Pharmaceuticals, has a Zacks Industry Rank of 78, placing it in the top 32% of over 250 industries [9] - Strong industry rankings correlate with better performance, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [9]